An Investigation on the Effect of BCc1 Nanomedicine on Gastric Cancer Patients Using EORTC QLQ-STO30 Questionnaire
| Author | Maryam Hafizi | en |
| Author | Somayeh Kalanaky | en |
| Author | Hassan Moaiery | en |
| Author | Maryam Khayamzadeh | en |
| Author | Sajad Noorian | en |
| Author | Vahid Kaveh | en |
| Author | Hossein Foudazi | en |
| Author | Behrooz Gharib | en |
| Author | Arash Jenabian | en |
| Author | Mohsen Razavi | en |
| Author | Saeid Salimi | en |
| Author | Saideh Fakharzadeh | en |
| Author | Afshin Zarghi | en |
| Author | Mohammad Hassan Nazaran | en |
| Author | Mohammad Esmaeil Akbari | en |
| Orcid | Maryam Hafizi [0000-0001-7417-6955] | en |
| Orcid | Hassan Moaiery [0000-0003-3221-476X] | en |
| Orcid | Maryam Khayamzadeh [0000-0002-4663-0118] | en |
| Orcid | Sajad Noorian [0000-0002-0924-1674] | en |
| Issued Date | 2019-11-30 | en |
| Abstract | Background: Nowadays, one criterion to assess the impact of various treatments in cancer patients is the quality of life (QOL), which represents the patients’ physical and psychosocial manner. It is already proved that BCc1 nanomedicine enjoys therapeutic behavior in cancer treatment of in vitro, animal, and human studies. Objectives: In the present study, we aimed at investigating the QOL in gastric cancer patients according to the European Organization for Research and Treatment of Cancer (EORTC QLQ-C30) questionnaire after treating them with BCc1 nanomedicine synthesized based on nanochelating technology. Methods: A randomized, double-blind, and multicenter study was conducted to investigate the QLQ-STO30 of 60 metastatic (8 weeks after treatment) and 60 non-metastatic (20 weeks after treatment) gastric cancer patients in two separate groups named BCc1 nanomedicine and placebo. Results: In the metastatic patients, the mean difference of overall QLQ-STO30 showed a 2.8-score improvement in BCc1 nanomedicine (P < 0.05) and a 5.2-score decline in placebo (P < 0.05); in non-metastatic patients, it showed a 2.3-score improvement in BCc1 nanomedicine (P > 0.05) and a 3-score decline in placebo (P > 0.05). Conclusions: The results of the study showed that BCc1 nanomedicine improves a number of indices in metastatic and non-metastatic gastric cancer patients, such as functional domains, symptom scales, and global QOL included in EORTC QLQ-STO30 questionnaire. | en |
| DOI | https://doi.org/10.5812/ijcm.94190 | en |
| Keyword | BCc1 Nanomedicine | en |
| Keyword | Quality of Life | en |
| Keyword | Nanomedicine | en |
| Keyword | Quality of Life; Nanomedicine; Nanochelating Technology | en |
| Publisher | Brieflands | en |
| Title | An Investigation on the Effect of BCc1 Nanomedicine on Gastric Cancer Patients Using EORTC QLQ-STO30 Questionnaire | en |
| Type | Research Article | en |
Files
Original bundle
1 - 1 of 1
Loading...
- Name:
- ijcm-12-11-94190.pdf
- Size:
- 135.08 KB
- Format:
- Adobe Portable Document Format
- Description:
- Article/s PDF